{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-24-000271","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.889485+00:00","generated_at":"2026-06-06T00:07:22.245933+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lexaria raises $3.6M in registered direct offering and private placement","bullets":["Gross proceeds of ~$3.6M from issuance of 1,558,443 shares at $2.31/share and pre-funded warrants at $2.3099.","Private placement issued unregistered warrants for up to 1,558,443 shares at $2.185 exercise price, 5-year term.","Net proceeds earmarked for R&D studies, patent/legal costs, and general working capital.","H.C. Wainwright acted as exclusive placement agent; fees equal 7% (6% for one investor) of gross proceeds plus agent warrants.","Officers and directors subject to 30-day lock-up on common stock and equivalents post-closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-24-000271","json":"https://secwatch.observer/filing/0001640334-24-000271.json","markdown":"https://secwatch.observer/filing/0001640334-24-000271.md","text":"https://secwatch.observer/filing/0001640334-24-000271.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000271/0001640334-24-000271-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000271/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T00:07:22.245933+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13b3d3f8d381c54e430c5d636420e2bab99db095","claim":"Lexaria Bioscience Corp. entered into Engagement Agreement with H.C. Wainwright & Co., LLC (effective 2024-02-12).","evidence_excerpt":"In connection with the Offering, on February 12, 2024, the Company entered into an engagement agreement (the “Engagement Agreement”) with H.C. Wainwright & Co., LLC (the “Placement Agent”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000271/0001640334-24-000271-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"H.C. Wainwright & Co., LLC"},{"label":"Effective","value":"2024-02-12"}],"fact_type":"material_agreement"},{"claim_id":"c3fd95bc5a1fbcdfcd5001afdf44d5febaf2e80b","claim":"Lexaria Bioscience Corp. entered into securities purchase agreement with certain institutional investors valued at approximately $3.6 million (effective 2024-02-14).","evidence_excerpt":"On February 14, 2024, Lexaria Bioscience Corp., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “SPA”) with certain institutional investors","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000271/0001640334-24-000271-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"approximately $3.6 million"},{"label":"Effective","value":"2024-02-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}